Premium
Combined oestrogen–progestogen replacement therapy does not inhibit low‐density lipoprotein oxidation in postmenopausal women
Author(s) -
Wen* Yichuan,
Doyle Miriam C. T.,
Norris Lucy A.,
Sinnott Margaret M.,
Cooke Thomas,
Harrison Robert F.,
Feely John
Publication year - 1999
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1999.00895.x
Subject(s) - progestogen , endocrinology , medicine , low density lipoprotein , antioxidant , hormone replacement therapy (female to male) , lipoprotein , estrogen , vitamin e , chemistry , cholesterol , biochemistry , testosterone (patch)
The use of oestrogen containing hormone replacement therapy (HRT) is related to a significantly reduced atherosclerotic cardiovascular risk in postmenopausal women. Oestrogen is thought to be antioxidant and may inhibit low-density lipoprotein (LDL) oxidation in vitro. We investigated the effect of combined oestrogen and progestogen HRT on LDL oxidation in postmenopausal women.